PUBLISHER: The Business Research Company | PRODUCT CODE: 1947047
PUBLISHER: The Business Research Company | PRODUCT CODE: 1947047
Recombinant DNA technology denotes the fusion of DNA molecules from diverse organisms, integrating them into a host organism to create new genetic combinations beneficial across scientific, medical, agricultural, and industrial domains. This technology plays a pivotal role in addressing health concerns by facilitating the development of novel medications and vaccines.
Within the realm of recombinant DNA technology, key product categories encompass recombinant protein drugs, vaccines, genetically modified crops, expression systems, cell and gene therapy, and gene editing. Notably, recombinant protein drugs serve crucial roles in biochemical analysis and medical diagnostics within human healthcare, including the production of antibodies, medicines, and vaccines. Renowned for their potency and rapid development compared to small molecules, these drugs are considered safer due to their reduced off-target adverse effects. This category comprises components like expression systems and cloning vectors. The extensive applications of recombinant DNA technology span various sectors such as food and agriculture, health and disease management, environmental interventions, and other diverse areas. This technology finds practical usage in biotechnology and pharmaceutical companies, academic and government research institutions, and various other end-use industries. Its impact is notably significant across a wide spectrum of fields and industries.
Tariffs are impacting the recombinant DNA technology market by increasing costs of imported laboratory reagents, cloning vectors, bioreactors, analytical instruments, and specialized consumables used in genetic engineering workflows. Biotechnology hubs in North America and Europe are most affected due to reliance on imported high-value research inputs, while Asia-Pacific faces higher costs for equipment-intensive manufacturing. These tariffs are increasing research and production expenses and extending development timelines. However, they are also encouraging domestic reagent manufacturing, localized bioprocessing infrastructure, and regional supply chain strengthening for critical biotechnology inputs.
The recombinant dna technology market research report is one of a series of new reports from The Business Research Company that provides recombinant dna technology market statistics, including recombinant dna technology industry global market size, regional shares, competitors with a recombinant dna technology market share, detailed recombinant dna technology market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant dna technology industry. This recombinant dna technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The recombinant dna technology market size has grown strongly in recent years. It will grow from $913.42 billion in 2025 to $998.83 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to expansion of molecular biology research, increasing incidence of chronic diseases, growth in biologics development, rising academic and government research funding, early commercialization of recombinant therapies.
The recombinant dna technology market size is expected to see strong growth in the next few years. It will grow to $1414.92 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to increasing investments in gene therapy development, rising demand for personalized medicine, expansion of CRISPR-based applications, growing focus on sustainable bioproduction, increasing collaboration between academia and industry. Major trends in the forecast period include increasing adoption of gene editing platforms, rising development of recombinant vaccines, growing use of advanced expression systems, expansion of cell and gene therapy pipelines, enhanced focus on scalable biomanufacturing.
The growing advancement of genetically modified crops is projected to drive the expansion of the recombinant DNA technology market in the future. Genetically modified crops are plants that have been intentionally altered at the genetic level using biotechnological methods. Recombinant DNA (rDNA) technology is utilized in the development of genetically modified (GM) crops by isolating genes that provide desired traits, creating recombinant DNA, inserting it into host crop cells, selecting and screening for successful integrations, regenerating transgenic plants, verifying trait expression, conducting field trials, securing regulatory approvals, and ultimately commercializing crops with enhanced characteristics. For example, in December 2023, the United States Department of Agriculture, a US-based government agency, reported that Canada planted 11.7 million hectares of genetically engineered (GE) crops, mainly including canola, soybeans, and corn. This marks a four percent increase from the previous year, largely due to the expansion of canola planting areas. Consequently, the growing development of genetically modified crops is fueling the growth of the recombinant DNA technology market.
Major companies operating in the recombinant DNA technology market are increasingly integrating advanced gene-editing approaches, including clustered regularly interspaced short palindromic repeats (CRISPR)-based recombinant DNA engineering, to improve precision, therapeutic effectiveness, and targeted genome modification. CRISPR-based recombinant DNA engineering is a molecular method that employs a guide ribonucleic acid (RNA) and the Cas9 enzyme to precisely identify and cut specific deoxyribonucleic acid (DNA) sequences, enabling targeted gene correction, controlled DNA insertion, and efficient genomic alteration. For example, in December 2023, Vertex Pharmaceuticals, a United States-based biotechnology company, in collaboration with CRISPR Therapeutics, a Switzerland-based gene-editing biotechnology company, received approval from the United States Food and Drug Administration for Casgevy, a CRISPR-enabled recombinant DNA therapy for the treatment of sickle cell disease and transfusion-dependent beta thalassemia. The therapy edits a patient's own stem cells to increase fetal hemoglobin production and incorporates features such as targeted DNA cleavage, high-fidelity gene modification, and ex vivo cell processing. Casgevy enhances treatment outcomes by enabling durable gene correction, reducing reliance on conventional therapies, and supporting long-term clinical benefits.
In October 2024, SK bioscience, a South Korea-based vaccine and biotechnology company, acquired IDT Biologika for an undisclosed consideration. Through this acquisition, SK bioscience seeks to expand its global manufacturing footprint, accelerate growth in recombinant vaccines as well as cell and gene therapy, and achieve a doubling of IDT Biologika's sales by 2028. IDT Biologika is a Germany-based contract development and manufacturing organization that provides services spanning vaccine production, recombinant vaccine development, viral vector manufacturing, and broader biopharmaceutical contract development and manufacturing activities.
Major companies operating in the recombinant dna technology market are Profacgen BioTech Corp, Amgen Inc, Novartis International AG, GenScript Biotech Corporation, Pfizer Inc, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A, Merck & Co. Inc, Biogen Inc, GlaxoSmithKline PLC, New England Biolabs Inc, Bayer CropScience, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc, bluebird bio Inc, Lonza Group AG, Horizon Discovery Group PLC, Sarepta Therapeutics Inc, Sangamo Therapeutics Inc
North America was the largest region in the recombinant DNA technology market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant dna technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the recombinant dna technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The recombinant DNA technology market includes revenues earned by entities by expression systems including mammalian, bacteria, yeast, and baculovirus / insect. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Recombinant DNA Technology Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses recombinant dna technology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for recombinant dna technology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The recombinant dna technology market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.